TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01972828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)
Description: in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)
Description: in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
Study: NCT02896023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: Induction of ovulation followed by ICSI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: Induction of ovulation followed by ICSI
Study: NCT01900314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
Study: NCT03005756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle guiding robot
Description: This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
Study: NCT03537456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mRDX-02-17
Description: mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5.
Study: NCT03611062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Executive Functions Training
Description: The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: VR Placebo Game
Description: In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
Study: NCT01225744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA \> 2 m2 .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT
Description: UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
Study: NCT01684800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A. Desmopressin 10 microgram
Description: 1 orally disintegrating tablet every night during study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B: Desmopressin 25 microgram
Description: 1 orally disintegrating tablet every night during study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C: Placebo
Description: 1 orally disintegrating tablet every night during study period
Study: NCT01815619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-site specimen evaluation
Description: The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: off-site specimen evaluation
Description: The specimen will be evaluated off-site by a cytopathologist
Study: NCT01286649

Intervention type: OTHER
Group type: OTHER
Intervention: Human autologous hair follicle cells
Description: Human autologous hair follicle cells suspended in cell medium

Intervention type: OTHER
Group type: OTHER
Intervention: Cell medium
Description: Cell medium
Study: NCT03346317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dried biological amnion graft
Description: Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate tablets+dydrogesterone tablets
Description: oral estradiol valerate tablets+dydrogesterone tablets
Study: NCT01748682

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A very low calorie diet of two different consistencies
Description: Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A very low calorie diet of two different consistencies
Description: Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
Study: NCT02723422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prehabilitation visit/increased physical therapy post-TAVR
Description: Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Arm
Description: Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
Study: NCT05967559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Flipped Learning Group
Description: The experimental group is the group that receives online flipped learning training.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional learning Group
Description: The control group is the group that received traditional learning training.
Study: NCT02298283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: is 1.8 mg/kg administrated by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncovin
Description: 1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: 100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 µg/kg/j, SC, D9 until GB 1.0x109/L

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30 Grays
Description: 30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
Study: NCT04558242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genix
Description: Low Level Light (LEDs)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Incandescent Bulbs Colored Red
Study: NCT04063527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: combination of paclitaxel and carboplatin
Study: NCT02261025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 75-100mg,per day
Study: NCT00688207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Extended Release)
Description: open-label, single, oral, 4mg dose
Study: NCT00870233

Intervention type: BEHAVIORAL
Intervention: online platform WEBCORE
Description: Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
Study: NCT01728233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
Study: NCT01723696

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C +prenatal vitamin
Description: Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet+prenatal vitamin
Study: NCT02778360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback NFT
Description: The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate MPH
Description: Drug prescribed with a first titration period until an optimal dose.
Study: NCT03095547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Pharmacokinetic assessment AUC 0-tau

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pharmacokinetic assessment AUC 0-tau

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Pharmacokinetic assessment AUC 0-tau

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Pharmacokinetic assessment AUC 0-tau

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Pharmacokinetic assessment AUC 0-tau

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Pharmacokinetic assessment AUC 0-tau

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmacokinetic assessment AUC 0-t
Study: NCT03271294

Intervention type: DEVICE
Group type: OTHER
Intervention: Exair Transvaginal Mesh
Description: Exair transvaginal mesh system for the treatment of pelvic organ prolapse
Study: NCT01987947

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two administrations by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quilizumab
Description: Two administrations by subcutaneous injection
Study: NCT00358072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postremission consolidation based on MRD status
Description: Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
Study: NCT00922701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
Study: NCT03346798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Photography
Description: Participants will engage in food photography on their smart phones while eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Food Photography
Description: Participants will engage in non-food photography on their smart phones while eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Phone Use
Description: Participants will not use their smart phones while eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Phone Use
Description: Participants will not use their smart phones while eating
Study: NCT00969280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized Acupuncture
Description: Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20\*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-acupuncture point shallow penetration acupuncture
Description: Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20\*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes.
Study: NCT01584570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min
Description: ECG monitoring for evaluation of QTc interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min
Description: ECG monitoring for evaluation of QTc interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min
Description: ECG monitoring for evaluation of QTc interval
Study: NCT03963401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
Study: NCT03279471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks based on their tolerability to the medication. Dosing is capped at 125mg/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT/BIACA
Description: Participants receive 16 weeks of BIACA therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
Study: NCT01326325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Drip continues of NaCl 0,9% in intravenous injection during 4 days
Study: NCT03631797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microvascular reactivity evaluation
Description: Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
Study: NCT02593045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH4102
Study: NCT00821327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, Sunitinib
Description: Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity.
Study: NCT01809977

Intervention type: PROCEDURE
Group type: OTHER
Intervention: collagen cross-linking procedure (total removal)
Description: patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: collagen cross-linking procedure (partial removal)
Description: patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
Study: NCT04115228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation and neuromodulation therapy
Description: The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
Study: NCT02703025

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GCB-70
Description: green coffee bean extract
Study: NCT00303628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV